STAT+: Pharmalittle: We're reading about cheap generic obesity drugs in India, high demand for estrogen patches and more
India's semaglutide patent expired March 20, 2026, and generic prices immediately crashed to roughly $14–15/month — while the same molecule costs over $1,000/month in the US. Generic semaglutide won't reach US pharmacies until 2033–2037 at the earliest, but Foundayo at $149/month self-pay and Zepbound's KwikPen at $299/month are the closest things to patent-cliff pricing available to you right now.
What This Means for You
India's semaglutide patent expired March 20, 2026, and generic prices immediately crashed to roughly $14–15/month — while the same molecule costs over $1,000/month in the US. Generic semaglutide won't reach US pharmacies until 2033–2037 at the earliest, but Foundayo at $149/month self-pay and Zepbound's KwikPen at $299/month are the closest things to patent-cliff pricing available to you right now.
India just ran the GLP-1 patent cliff experiment, and the results are exactly as stark as you’d expect. Novo Nordisk’s core semaglutide product patent in India expired on March 20, 2026. Torrent Pharmaceuticals was first to market, launching two branded generics — Sembolic and Semalix — in both oral and injectable forms on the same day. According to market research firm Pharmarack, semaglutide’s share of India’s GLP-1 market jumped from 25% in February to 33% in March — in a single month, before most patients had even heard the patent had expired. Torrent alone captured 8% market share. Generic prices landed at roughly ₹1,200/month (approximately $14–15 USD). The same molecule costs over $1,000/month in the US without insurance.
The collateral damage is equally revealing. Eli Lilly’s tirzepatide (Mounjaro in India), which remains under patent through 2035–2036, watched its market share fall from 71% to 64% in March — not because tirzepatide became less effective, but because a much cheaper competitor appeared overnight. Monthly Mounjaro sales declined from 1.35 billion rupees ($14.5M) to 1.14 billion rupees in a single month. This is the textbook patent-cliff dynamic: the moment a “good enough” option appears at a fraction of the price, patients and payers switch — even from a clinically superior drug. India’s total GLP-1 market is projected to expand nearly five-fold to ₹8,000 crore (approximately $960M USD) by 2030, driven almost entirely by generic volume.
The US situation is a policy construct, not a scientific constraint. These molecules cost $10–30/month to manufacture at industrial scale; the $1,000+ US retail price reflects patent exclusivity, PBM dynamics, and a drug coverage system that historically excluded obesity as an indication. Core semaglutide patents in the US are expected to expire between 2031 and 2035 depending on formulation, with FDA generic review adding another 12–18 months. Affordable domestic generics are realistically a 2033–2037 story. Tirzepatide’s US patent protection runs through the mid-to-late 2030s — even longer.
India’s March 2026 data should change how you think about the prices you’re being asked to pay today. The manufacturing cost argument for $1,000/month US pricing is officially dead — India proved it. Every dollar you spend above Foundayo’s $149/month starting price or Zepbound’s $299/month KwikPen tier is patent rent, not cost recovery. Push for savings cards, use telehealth providers that negotiate volume pricing, and watch whether the Medicare GLP-1 Bridge program launching July 2026 at $245/month applies to your situation.
Frequently Asked Questions
When will generic semaglutide actually be available to US patients?
US generic availability depends on patent expiry plus FDA review time. Novo Nordisk’s core semaglutide patents are expected to expire between 2031 and 2035, depending on formulation — injectable versus oral versions have different patent landscapes. Generic manufacturers then need 12–18 months for FDA review under the Abbreviated New Drug Application process. Absent successful patent challenges or early licensing deals from Novo, affordable generic semaglutide in US pharmacies is realistically a 2033–2037 event.
Are Indian generic semaglutide products safe to import for personal use?
No — and this is worth being direct about. Importing prescription drugs from India for personal use violates US law and carries real safety risks. Indian generics sold domestically aren’t FDA-reviewed. The products Torrent launched for the Indian market (Sembolic, Semalix) have not been evaluated by the FDA for US use. Manufacturing quality for domestically sold Indian generics varies by company, and you have no way to verify it from a US address. Don’t order them online. The legal and safety risks aren’t theoretical.
What does tirzepatide’s (Zepbound/Mounjaro) US patent timeline look like?
Tirzepatide’s patents are newer and more layered than semaglutide’s. The primary US patents on the compound are expected to run through the mid-to-late 2030s, with formulation-specific patents potentially extending further. The market share loss Mounjaro experienced in India in March 2026 wasn’t from tirzepatide’s own generics — it was patients switching to semaglutide generics. Tirzepatide won’t face direct generic competition in any major market until the late 2030s at the absolute earliest.
Keep Reading
Original source
Read the full article at STAT News